Gene

CDKN2B

cyclin dependent kinase inhibitor 2B

Explore in graph →CI-GENE-00040781HGNC:1788 ENSG00000147883 NCBI 1030 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (8)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AXIN2 P455K + BAX L76R + BRAF V600E + CDKN2A Deletion + CDKN2B Deletion + TET2 E796KCDKN2B TET2 BAX AXIN2 BRAF CDKN2A1

Cohorts

Alteration frequency by cohort (19)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved19 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Skin Cutaneous Melanoma TCGA-SKCM	Cutaneous Melanoma	Ssm

Literature

Linked publications (3)

25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia.
· Leukemia · 2006 · PMID 16307009 · validated civic_curation pubmed
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
· Anticancer Res · 2013 · PMID 23898052 · validated civic_curation pubmed
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
· Oncotarget · 2016 · PMID 27286459 · validated civic_curation pubmed

CDKN2B Loss2
Palbociclib	Renal Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1374 Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 lo… (full text at CIViC) PMID 23898052 · Logan et al., 2013 · Open in CIViC	civic
Linsitinib + PalbociclibSubstitutes	Ewing Sarcoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID1880 A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohort… (full text at CIViC) PMID 27286459 · Murakami et al., 2016 · Open in CIViC	civic

CDKN2B Loss2

Palbociclib

Renal Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID1374

Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 lo… (full text at CIViC)

PMID 23898052 · Logan et al., 2013 · Open in CIViC

civic

Linsitinib + PalbociclibSubstitutes

Ewing Sarcoma

Predictive

Supports Sensitivity Response

accepted

EID1880

A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohort… (full text at CIViC)

PMID 27286459 · Murakami et al., 2016 · Open in CIViC

civic

CDKN2B METHYLATION1
(prognostic)	Acute Promyelocytic Leukemia	Prognostic	B	Supports Poor Outcome	4	accepted	EID1848 This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6… (full text at CIViC) PMID 16307009 · Chim et al., 2006 · Open in CIViC	civic

CDKN2B METHYLATION1

(prognostic)

Acute Promyelocytic Leukemia

Prognostic

Supports Poor Outcome

accepted

EID1848

This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6… (full text at CIViC)

PMID 16307009 · Chim et al., 2006 · Open in CIViC

civic

CDH1 MUTATION + CDKN2A Mutation + CDKN2B Mutation + FGFR2 MutationFGFR2 CDH1 CDKN2A CDKN2B1
Crizotinib + Palbociclib Regimen + PazopanibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID12777 In a case report of metastatic cholangiocarcinoma harboring an FGFR2 W290_P307>C (16.25% Variant allele frequency) alteration together with CDH1 Q677fs*7 (23.1% VAF) and CDKN2A/B frameshift mutations … (full text at CIViC) PMID 38645422 · Aydın et al., 2024 · Open in CIViC	civic

CDH1 MUTATION + CDKN2A Mutation + CDKN2B Mutation + FGFR2 MutationFGFR2 CDH1 CDKN2A CDKN2B1

Crizotinib + Palbociclib Regimen + PazopanibCombination

Cholangiocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID12777

In a case report of metastatic cholangiocarcinoma harboring an FGFR2 W290_P307>C (16.25% Variant allele frequency) alteration together with CDH1 Q677fs*7 (23.1% VAF) and CDKN2A/B frameshift mutations … (full text at CIViC)

PMID 38645422 · Aydın et al., 2024 · Open in CIViC

civic

CDKN2A Deletion + CDKN2B Deletion + ERG Deletion + IKZF1 Deletion + CRLF2 Fusion + PAX5 DeletionPAX5 CDKN2B ERG IKZF1 CRLF2 CDKN2A1
(prognostic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	submitted	EID7786 83 of 991 cases of pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) were found to have IKZF1 deletion, previously reported as an independent factor associated with a poor prognosis.… (full text at CIViC) PMID 29498923 · Stanulla et al., 2018 · Open in CIViC	civic

CDKN2A Deletion + CDKN2B Deletion + ERG Deletion + IKZF1 Deletion + CRLF2 Fusion + PAX5 DeletionPAX5 CDKN2B ERG IKZF1 CRLF2 CDKN2A1

(prognostic)

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Prognostic

Supports Poor Outcome

submitted

EID7786

83 of 991 cases of pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) were found to have IKZF1 deletion, previously reported as an independent factor associated with a poor prognosis.… (full text at CIViC)

PMID 29498923 · Stanulla et al., 2018 · Open in CIViC

civic

CDKN2A Loss + CDKN2B Loss + KRAS G12D + KRAS G12R + SMAD4 Deletion + TP53 R267WKRAS TP53 CDKN2A CDKN2B SMAD41
Bevacizumab + Palbociclib + TrametinibCombination	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	submitted	EID11711 In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (63 y/F) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC) PMID 36670111 · Shaya et al., 2023 · Open in CIViC	civic

CDKN2A Loss + CDKN2B Loss + KRAS G12D + KRAS G12R + SMAD4 Deletion + TP53 R267WKRAS TP53 CDKN2A CDKN2B SMAD41

Bevacizumab + Palbociclib + TrametinibCombination

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID11711

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (63 y/F) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

civic

CDKN2A Loss + CDKN2B Loss + KRAS G12D + KRAS G12R + TP53 R267WKRAS TP53 CDKN2A CDKN2B1
Bevacizumab + Palbociclib + TrametinibCombination	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	submitted	EID11710 In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (69 y/M) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC) PMID 36670111 · Shaya et al., 2023 · Open in CIViC	civic

CDKN2A Loss + CDKN2B Loss + KRAS G12D + KRAS G12R + TP53 R267WKRAS TP53 CDKN2A CDKN2B1

Bevacizumab + Palbociclib + TrametinibCombination

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID11710

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (69 y/M) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

civic